Semax vs ARA-290
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Semax is a synthetic heptapeptide derived from ACTH developed in Russia. It is a potent nootropic that enhances memory, focus, and provides neuroprotection. Approved in Russia for cognitive disorders, stroke recovery, and traumatic brain injury.
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- Half-Life
- Minutes (but effects persist for hours via BDNF induction)
- ~2–4 hours (SC administration)
- Admin Route
- Intranasal, SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.25–1 mg (250–1000 mcg)
- 4 mg (fixed dose)
- Frequency
- 1–2 times daily
- Once daily
- Key Benefits
- Enhances memory and learning
- Improves focus and concentration
- Increases mental energy and motivation
- Provides neuroprotection via BDNF and NGF upregulation
- Reduces cognitive decline
- May alleviate ADHD symptoms
- Supports recovery from brain injury and stroke
- Fast-acting — effects within 30–60 minutes
- Approved in Russia for cognitive disorders and stroke recovery
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Side Effects
- Headache (rare, often from higher doses)
- Anxiety or overstimulation at high doses
- Sleep disruption if dosed too late
- Irritability (uncommon)
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Stacks With
- —
- —